abiraterone + enzalutamide + docetaxel

The combination of abiraterone, enzalutamide, and docetaxel is an investigational triplet therapy used in treating metastatic castration-resistant prostate cancer (mCRPC). **Abiraterone** is a selective and irreversible inhibitor of CYP17A, a key enzyme in androgen biosynthesis, leading to decreased androgen levels. **Enzalutamide** is a potent androgen receptor (AR) signaling inhibitor, blocking AR binding, nuclear translocation, and DNA transcription activation. **Docetaxel** is a microtubule inhibitor classified as a taxane chemotherapy, which inhibits mitosis by stabilizing microtubules and disrupting cell division. This triplet therapy targets both androgen signaling and cell division, aiming for synergistic antitumor effects in advanced prostate cancer. There is evidence for clinical benefit of adding abiraterone or enzalutamide to docetaxel, with improved outcomes in progression-free survival and metastasis response, and manageable toxicity profiles. However, significant cross-resistance may limit sequential and concurrent efficacy, and triple-regimen studies remain ongoing[2][3][4][6].